Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Hypothetical Scenario of an ATE Buyout

<< Previous

Bullboard Posts

Next >>

Comment by IrishCanuckon Nov 18, 2020 9:36pm

261 Views

Post# 31928256

RE:Hypothetical Scenario of an ATE Buyout

There are a lot of Billions in this article from 2017 for osteoarthritis...

https://www.biospace.com/article/rumor-alert-sanofi-close-to-scooping-up-this-massachusetts-biotech-in-1-billion-deal-/

I dream of a 2 billion CAD minimum, for all three drugs and IP which is only 1.5 billion USD. Sometimes I think that's a lot and then I realize how much money is tossed aorund for nothing in the US. There are no rules to measure this, sometimes it's jsut a bidding war

<< Previous

Bullboard Posts

Next >>

Dollar Tree CEO Rick Dreiling steps down as discount retailer struggles